Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.57 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 3/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22208414 | 0.88 | CNR2 (0.47) | RIPK1DYRK1AOPRK1CNR2CNR1 | |
| SCHEMBL22208379 | 0.84 | DYRK1A (0.44) | RIPK1DYRK1A | |
| SCHEMBL22208451 | 0.84 | DYRK1A (0.43) | RIPK1DYRK1AGSK3BCNR1KDM1A | |
| SCHEMBL22208372 | 0.79 | OPRK1 (0.41) | RIPK1OPRK1HDAC3HDAC1HDAC2 | |
| SCHEMBL22224034 | 0.79 | RIPK1 (0.51) | RIPK1DYRK1AGSK3BKCNH2HPGDS | |
| SCHEMBL22208359 | 0.78 | FNTA (0.42) | RIPK1OPRK1KCNH2HDAC6CNR2 | |
| Methane SCHEMBL22208422 | 0.78 | OPRK1 (0.41) | RIPK1OPRK1HDAC3HDAC1HDAC2 | |
| SCHEMBL22208455 | 0.78 | DYRK1A (0.51) | DYRK1AOPRK1GSK3BKCNH2HDAC3 | |
| SCHEMBL22208416 | 0.73 | PIK3CG (0.50) | DYRK1AOPRK1HDAC3HDAC1HDAC2 | |
| SCHEMBL22208319 | 0.72 | KDM4E (0.37) | DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421226-B2 | Heteroaryl compounds as necrosis inhibitors, composition and method using the same | ACCRO BIOSCIENCE (HK) LIMITED (HK) | 2025-09-23 | — | — | US | disclosed |
| US-20220112188-A1 | HETEROARYL COMPOUNDS AS NECROSIS INHIBITORS, COMPOSITION AND METHOD USING THE SAME | ACCRO BIOSCIENCE (HK) LIMITED (HK) | 2022-04-14 | — | — | US | disclosed |
| EP-3908277-A1 | HETEROARYL COMPOUNDS AS NECROSIS INHIBITORS, COMPOSITION AND METHOD USING THE SAME | Zhang, Xiaohu (CN) | 2021-11-17 | — | — | EP | disclosed |
| WO-2020146858-A1 | HETEROARYL COMPOUNDS AS NECROSIS INHIBITORS, COMPOSITION AND METHOD USING THE SAME | ACCRO BIOSCIENCE INC. (KY) | 2020-07-16 | — | — | WO | disclosed |
| WO-2020146858-A1 | HETEROARYL COMPOUNDS AS NECROSIS INHIBITORS, COMPOSITION AND METHOD USING THE SAME | ACCRO BIOSCIENCE INC. (KY) | 2020-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421226-B2 | Heteroaryl compounds as necrosis inhibitors, composition and method using the same | TNF, LITAF, PNLIP | RIPK1 224/4885DYRK1A 4546/4885OPRK1 2166/4885 |
| US-20220112188-A1 | HETEROARYL COMPOUNDS AS NECROSIS INHIBITORS, COMPOSITION AND METHOD USING THE SAME | TNF, LITAF, PNLIP | RIPK1 224/4885DYRK1A 4546/4885OPRK1 2166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.